IDEAYA Biosciences
7000 Shoreline Court
Suite 350
South San Francisco
California
94080
United States
Tel: 650-443-6209
Website: http://www.ideayabio.com/
About IDEAYA Biosciences
Founded in 2015, IDEAYA Biosciences is a public, clinical-stage synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using DNA sequencing and other molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response.
Stock Symbol: IDYA
182 articles about IDEAYA Biosciences
-
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
3/12/2024
IDEAYA Biosciences, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate IDE161, the company's investigational, potential first-in-class, small molecule poly glycohydrolase, or PARG, inhibitor, in combination with KEYTRUDA® Merck's anti-PD-1 therapy, in patients with microsatellite instability-, or MSI-, high and microsatellite stable, or MSS, endometrial cancer, in a Phase 1 clinical trial.
-
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
3/4/2024
IDEAYA Biosciences, Inc. announced its participation in upcoming investor relations events.
-
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
2/20/2024
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the quarter and full-year ended December 31, 2023.
-
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
2/1/2024
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - January 26, 2024
1/26/2024
IDEAYA Biosciences, Inc. today announced that, on January 25, 2024 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 123,000 shares of the Company's common stock to three newly hired employees.
-
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
1/7/2024
IDEAYA Biosciences, Inc. announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates.
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 29, 2023
12/29/2023
IDEAYA Biosciences, Inc. announced that, on December 28, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 18,500 shares of the Company's common stock to a newly hired employee.
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/8/2023
IDEAYA Biosciences, Inc. today announced that, on November 30, 2023 , the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 40,000 shares of the Company's common stock to a newly hired employee.
-
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
12/5/2023
IDEAYA Biosciences, Inc. announced its participation in upcoming investor relations event.
-
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
12/3/2023
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day.
-
IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
11/7/2023
IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2023.
-
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference
11/1/2023
IDEAYA Biosciences, Inc. announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2023.
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 27, 2023
10/27/2023
IDEAYA Biosciences, Inc. announced that, on October 26, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 48,000 shares of the Company's common stock to a newly hired employee.
-
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
10/27/2023
IDEAYA Biosciences, Inc. announced the closing of its underwritten public offering of 5,797,872 shares of its common stock at a public offering price of $23.50 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 319,150 shares of common stock at a public offering price of $23.4999 per pre-funded warrant, before underwriting discounts and commissions.
-
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
10/24/2023
IDEAYA Biosciences, Inc. announced that it intends to offer and sell up to $125.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering.
-
IDEAYA Announces Pricing of Public Offering
10/24/2023
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
-
IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline
10/23/2023
IDEAYA Biosciences, Inc. announces clinical data presented at a proffered paper session of the European Society of Medical Oncology Congress 2023 from the company's ongoing Phase 2 clinical trial evaluating darovasertib in combination with crizotinib in patients having metastatic uveal melanoma.
-
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
10/17/2023
IDEAYA Biosciences, Inc. announces the publication of the abstract for a proffered paper session at the European Society of Medical Oncology Congress 2023 relating to selected clinical data from the company's ongoing Phase 2 clinical trial evaluating darovasertib in combination with crizotinib in patients having metastatic uveal melanoma.
-
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma
10/16/2023
IDEAYA Biosciences, Inc. announces initiation of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma.
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 06, 2023
10/6/2023
IDEAYA Biosciences, Inc. announced that, on September 28, 2023, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company's common stock to a newly hired employee.